Business
Propanc Biopharma Publishes Key Data in Peer Reviewed Journal Confirming Anti-Tumor Potential of Proenzymes
Current Research Shows Proenzymes Decreases Cell Proliferation and Migration, Induces Cell Differentiation, Impairs Angiogenesis and Reduces the Metastatic
About this update from Propanc Biopharma, Inc.
[{"type":"text","content":"\nCurrent Research Shows Proenzymes Decreases Cell Proliferation and Migration, Induces Cell Differentiation, Impairs Angiogenesis and Reduces the Metastatic Potential of Cancer Stem Cells\n\n MELBOURNE, Australia--(BUSINESS WIRE)--\nPropanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced today that the Company’s scientific researchers, together with its joint research partners, Universities of Jaén and Granada, published key data in a peer reviewed journal, Expert Opinion on Biological Therapy, confirming the anti-tumor potential of a mixture of two pancreatic proenzymes trypsinogen and chymotrypsinogen. Treatment with proenzymes sensitizes cancer stem cells (CSCs) which may allow standard treatment approaches, like chemotherapy and radiotherapy to be more effective. Expert Opinion on Biological Therapy is a peer-reviewed medical journal covering research on all aspects of biological therapies. The article is entitled “Trypinsogen and chymotrypsinogen: potent anti-tumor agents,” and can be accessed via the link: https://www.tandfonline.com/eprint/MJ7Y7EWCJI9CHESREZUC/full?target=10.1080/14712598.2021.1922666\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210517005041/en/Main anti-tumor effects of Proenzymes (Photo: Business Wire)\nThe article is the fifth scientific publication published on the effects of proenzymes in cancer and fourth published in a peer reviewed journal. The current research demonstrates that novel pancreatic proenzyme formulations exert the following effects on CSCs:\n\n\nDecreases cell proliferation and migration;\n\n\nInduces cell differentiation on CSCs to become benign;\n\n\nImpairs angiogenesis (tumor blood vessel formation); and\n\n\nReduces the metastatic potential of CSCs.\n\n\n“We continue to publish compelling scientific data confirming the effects of proenzymes against CSCs and its potential as a targeted therapy,” said Dr Julian Kenyon, Propanc’s Chief Scientific Officer, “There is currently significant interest in therapies that are not only more effective and less toxic, but critically, also support the immune function of patients. Given the current global pandemic situation, the risk of ...